in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Piramal and Lilly Enter Major Drug Development Deal
1:00 PM MDT | July 25, 2007 | Deepti Ramesh
Eli Lilly and Nicholas Piramal India Ltd. (NPIL; Mumbai), one of India’s biggest manufacturers of pharmaceuticals, have signed a major agreement to develop and market some of Lilly’s preclinical drug candidates covering a wide range of therapeutic areas. The agreement sets a new pattern in alliances for drug discovery and development, experts say. NPIL will be responsible for design and execution of the program, and the resulting developmental drugs will be registered with U.S. FDA as Investigational New Drug Applications (IND). Lilly and NPIL will...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee